The independently developed "COVID-19 antigen detection kit SARS-COV-2 Nucleocapsid (N) Antigen Rapid Detection Kit (Colloidal gold method)" by Synthgene Medical Technology was approved by the UK 5-year CTDA certification.

Following the broader life science tools space, proteomics firms experienced something of a retrenchment in 2022 as the boom times of the previous two years gave way to layoffs, strategic realignments, and delays.

For its first full quarter following a business combination, QuidelOrtho after the close of the market on Wednesday reported third-quarter revenues of $783.8 million, an increase of 54% compared to $509.8 million in Q3 2021 and in line with preliminary estimates announced in October.

At-home and point-of-care diagnostics company OraSure Technologies said Tuesday it secured a federal contract for up to 1 million of its OraQuick In-Home HIV Tests over five years.

Chinese diagnostic firm Amoy Diagnostics announced on Wednesday that it has entered into a collaboration agreement with French pharmaceutical firm Pierre Fabre to develop companion diagnostic kits in China.

SQI Diagnostics said on Monday that it has signed a definitive agreement to acquire Precision Biomonitoring's SARS-CoV-2 testing business and related molecular diagnostic technology for $6.825 million in cash and stock.

The Japan Ministry of Health, Labour and Welfare (MHLW), Japan's regulatory agency, has granted approval to the Thermo Fisher Scientific's Oncomine Dx Target Test to be used as a companion diagnostic to identify patients with RET-fusion positive non-small cell lung cancer (NSCLC).

NEW YORK – Qiagen said on Thursday that it has formed a global strategic alliance with Japan's Sysmex to develop and commercialize cancer companion diagnostics using Sysmex's Plasma-Safe-SeqS next-generation sequencing technology.

Recently, South Korean idol Song Joong Ki endorsed SD BIOSENSOR, an in vitro diagnostic company, sparking heated discussions in the IVD industry.

Roche announced on the 15th that it will acquire GenMark Diagnostics, a US molecular pathology laboratory manufacturer, for US$1.8 billion.